In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  

In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding the latest advances in the treatment of myelodysplastic syndromes. These findings were presented at the 4^th Annual Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit.

At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Teresa Knoop, MSN, RN, AOCN^® gave a presentation on updates surrounding pharmacology. Oncology Data Advisor followed up with her, asking for advice on how to provide optimal pharmacological care for patients with cancer. 

At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Oncology Data Advisor spoke with Nazy Zomorodian, NP, a nurse practitioner in the Department of Urology at the University of California Los Angeles (UCLA) Medical Center, about strategies for optimizing patient experiences during renal cell carcinoma treatment. Ms. Zomorodian discusses the challenges of treating patients with renal cell carcinoma, particularly during the COVID-19 pandemic, and shares strategies for promoting adherence and optimizing treatment outcomes.